The content on this site is intended for healthcare professionals only
Dr Doroshow (National Cancer Institute, Bethesda, USA), Dr Flaherty (Massachusetts General Hospital, Boston, USA) and Dr Conley (Division of Cancer Treatment & Diagnosis, NCI , USA) present, at a press conference at ASCO 2015, about the trial: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)
A clinical trial that will analyse patients’ tumours to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assign treatment based on the abnormality.
SABCS 2025: Latest developments in multigene testing in early breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
New classification for identifying HR myeloma based on cytogenetic abnormalities
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
